CTOs on the Move

Nivano Physicians

www.nivanophysicians.com

 
Nivano Physicians is an Independent Physician Association (IPA) that operates within Sacramento and surrounding counties. They are committed to advocating for the Medi-Cal community and ensuring that managed healthcare is manageable.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

The Green Organic Dutchman

The Green Organic Dutchman Ltd. produces farm grown, high quality organic medical cannabis in small batches using craft growing, all natural and organic principles. The Green Organic Dutchman Ltd. is licensed under the Access to Cannabis for Medical Purposes Regulations (ACMPR) to cultivate medical marijuana. The Green Organic Dutchman carries out its principal activities producing marijuana from its facilities located on a 100-acre farm in Ancaster, Ontario, pursuant to the provisions of the ACMPR and the Controlled Drugs and Substances Act (Canada) and its regulations.

MedRepublic

We`ve created a global health marketplace where patients are empowered to make the healthcare choices that work for them.

National Dental Association

National Dental Association is a Washington, DC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Heritage Enterprises

Heritage Enterprises Inc. is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Heritage Enterprises Inc. is based in Bloomington, IL. You can find more information on Heritage Enterprises Inc. at www.heritageofcare.com

Xenon Pharmateuticals

Xenon Pharmaceuticals (NASDAQ:XENE) – a biopharmaceutical company with operations in Vancouver, BC, Canada and Boston, MA, U.S.A. – is committed to delivering innovative medicines to provide a brighter future for patients suffering from neurological disorders. At Xenon, we are advancing an exciting pipeline of neurology-focused therapies, with a particular emphasis on novel treatments for both adult and pediatric patients with epilepsy. XEN496 is currently being evaluated in the Phase 3 “EPIK” clinical trial in young patients with KCNQ2-DEE, a rare and severe form of childhood epilepsy. Late-stage development plans are also underway for our XEN1101 program, building upon the compelling data from the Phase 2b “X-TOLE” study in adult patients with focal epilepsy. We are also proud of the leading-edge science coming out of our discovery labs, with many early-stage research programs underway. In addition to Xenon`s proprietary programs, we have ongoing collaborations with our valued pharmaceutical partners. With a healthy balance sheet to support our growth plans, we continue to build a fully-integrated, premier neuroscience company with strong discovery, development, and commercial operations. Our employees are smart, passionate, dedicated, and driven by their incredibly important work to discover, develop, and deliver new medicines for patients in need. Building and maintaining a respectful, collaborative, inclusive, and productive culture is a priority for us. We are looking for great people who thrive in a fast-paced, dynamic work environment to join our team during this transformative time for Xenon.